▮ Slide Shows

▮ Entertainment

Top Stories
Game of Thrones
▮ Music news
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

▮ Content Licensing

▮ Premium NEW

▮ More

$5 And Under

Marathon Patent Group (MARA) Has Jumped To A 7-Month High

By RTTNews Staff Writer ✉ | Published: 11/24/2017 9:37 AM ET

Marathon Patent Group (MARA) has gapped open sharply higher Friday morning and is now up 1.50 at $3.68 on above average volume.

Marathon Patent Group has leaped to a 7-month high. The stock has been rising since the company reported third quarter results earlier this week.

For comments and feedback contact: editorial@rttnews.com

Get Access to Premium Stock Alerts with RTT Biotech Investor.

Biotech stocks Facing FDA Decision in January 2023

Biotech stocks Facing FDA Decision in January 2023

Biotech Stocks Facing FDA Decision In December 2022

Biotech Stocks Facing FDA Decision In December 2022

Biotech Stocks Facing FDA Decision In November 2022

Biotech Stocks Facing FDA Decision In November 2022

Latest Updates on COVID-19

U.S. Covid Metrics Signal Ease In Pandemic

FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots

US Covid Deaths Rise By 78% In 2 Weeks

78% Increase In US Covid Deaths In A Fortnight

Pentagon Repeals Memo Mandating Covid Vaccination For Armed Forces

Read More

COVID-19: Drugs in Development

Follow RTT

Editor's Pick
Most Read
Most Emailed

Chevron Q4 Profit Up 25%, But Misses Estimates

ZLINE Expands Recall Of Gas Ranges

FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots

Drizzilicious Mini Rice Cake Bites, Popcorn Recalled

Comcast Q4 Profit Edges Down, But Results Top Estimates

Meta To Reinstate Donald Trump's Facebook, Instagram Accounts

Almondy Chocolate Cake With Daim Recalled

Amazon Workers At UK Warehouse On Strike

Boeing Q4 Loss Sharply Narrows; Results Miss Estimates

AT&T Slips To Loss On Charges, But Adj. EPS Tops View

ASML Q4 Profit Up, Bookings Down; Sees Growth In FY23

FDA Bans 2 Vuse Menthol E-cigarette Products

Johnson & Johnson Q4 Profit Down 26%, But Adj. EPS Tops Estimates

SkinnyDipped Dark Chocolate Nut Products Recalled

Cidara: FDA Committee Recommends FDA Approve Rezafungin For Candidemia, Invasive Candidiasis

Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma

Altamira: NASAR Interim Analysis Shows Superior Efficacy Of Bentrio In Seasonal Allergic Rhinitis

Intuitive Surgical Inc. Q4 Profit Decreases, misses estimates

Kura Oncology Announces FDA Clearance For IND Application For KO-2806

Emerson Says Committed To Proceed With National Instruments' Acquisition

Syros Gets Fast Track Designation In U.S. For Tamibarotene For Myelodysplastic Syndrome Treatment

Lonza FY22 Profit Up, Lifts Dividend; Sees Higher FY23 Sales, Weak Margin; Plans CHF 2 Bln Buyback

Abbott Issues FY23 Earnings, Sales Growth View - Update

FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots

Ford To Reportedly Cut 3,200 Jobs In Europe

Eastern Bankshares Down 11% As Q4 Earnings Fell Shy Of Estimates

Brown & Brown Q4 Profit Rises

Ipsen: CHMP Recommends Not To Grant Marketing Authorization For Palovarotene As Treatment For FOP

Archer-Daniels-Midland Q4 Profit Increases, beats estimates

Capital One Financial Corp. Q4 Profit Decreases, misses estimates

CNX Resources Corporation Q4 Income Climbs

Community Bank System Q4 Profit Beats Estimates

General Electric Co Q4 Earnings Summary

Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease

Syros Gets Fast Track Designation In U.S. For Tamibarotene For Myelodysplastic Syndrome Treatment

Newell Brands To Cut Jobs